Follow this Page for updates
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects phosphatidylcholine has on your body, and how strong these effects are.
|Grade||Level of Evidence|
|Robust research conducted with repeated double-blind clinical trials|
|Multiple studies where at least two are double-blind and placebo controlled|
|Single double-blind study or multiple cohort studies|
|Uncontrolled or observational studies only|
Level of Evidence
? The amount of high quality evidence. The more evidence, the more we can trust the results.
Magnitude of effect
? The direction and size of the supplement's impact on each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
Consistency of research results
? Scientific research does not always agree. HIGH or VERY HIGH means that most of the scientific research agrees.
|HDL-C||-||- See study|
|LDL-C||-||- See study|
|Total Cholesterol||-||- See study|
|Triglycerides||-||- See study|
Table of Contents:
Phosphatidylcholine appears to be the second most important phospholipid endogenously in the human body (second to sphingolipids) and is generally seen as ubiquitous.
In cell membranes, most phospholipids are based off of phosphatidylcholine with phosphatidylserine contributing a significant portion.
Phosphatidylcholine (PC) is a phospholipid with two fatty acids (these can vary within the molecule and it is still referred to as PC) bound to a glycerol backbone, with the final binding slot occupied by a phosphatic acid and then a choline molecule; demethylation of all methyl groups on the choline results in phosphatidylethanolamine (both phospholipids being common in the diet and sourced in soy lecithin).
If phosphatidylcholine loses both of its fatty acids and retains its choline group, it is referred to as Alpha-GPC.
34g of phosphatidylcholine (conferring 2,600mg of choline) failed to significantly influence the cholesterol profile of otherwise healthy aged men over the course of two weeks.
Supplementation of 2.6g choline via 34g phosphatidylcholine (soybean) over the course of two weeks in otherwise healthy men (aged 50-71) appears to be able to increase circulating triglycerides (8%) relative to placebo (the fatty acid profile of the lecithin replicated, but without PC).
Phosphatidylcholine (PC) injections (usually as 70% PC with deoxycholate at 4.2% as solvent and benzyl alcohol at 3% as preservative) appear to be used for inducing lipolysis (or alternatively, lipid dissolution) with all three agents (but mostly deoxycholate) able to induce adipocyte bursting followed by an increase in triglyceride-rich lipoproteins. It appears to be associated with low rates of significant side-effects when used under the guidance of medical professionals although adverse effects have been reported in case studies.
Injections of PC have been used in models of lipodystrophy (a redistibution of adipose tissue in an abnormal manner, commonly seen in HIV patients), where excised cells from lipodystrophic AIDS patients treated with 20mcg/mL of the above injection mixture lysed within 4-5 hours. In a trial on persons with gynoid lipodystrophy, injections of phosphatidylcholine/deoxycholate (4 injections over 8 weeks) appears to reduce localized fat although the a similar level of efficacy as deoxycholate alone.
Two pilot studies have assess orbital fat pads (under the eye) has noted that 0.4-0.5mL of PC have noted mixed effects, with benefit and null results. Benefit has been noted in a small trial on jaw fat, although there was no control group used (benefits noted relative to baseline).
One study has been conducted assessing visceral adipose (a hardened faty surrounding internal organs), and in this animal model (dogs) there was an apparent lipolytic effect following injections. Animal models have also noted lipolytic effects in rat inguinal fat pads as well.
Adipose tissue necrosis can be induced in vitro with such an infusion of PC that may affect other cell types; necrosis of adipose is sometimes observed in animal models although not all the time. Long term cost-benefit analyses of safety regarding PC/deoxycholate injections have not yet been undertaken.
Injections of a mixture of deoxychlorate and phosphatidylcholine appear to be commonly used for localized fat loss, most commonly studied for lipodystrophies. Phosphatidylcholine may play a role here, but the trial sizes are relatively small and those used in more hedonistic models (aesthetic fat loss rather than lipodystrophy) are less than optimally structured although theoretically it should apply to all fat deposits. A clear cost-benefit analysis has not yet been conducted
Oral phosphatidylcholine is unlikely to possess such effects as those noted with injections
750mg of phosphatdylcholine to pregnant mothers from 18 weeks gestation to 90 days postpartum (in addition to around 360mg of choline in the diet) has failed to enhance the brain function of the offspring, suggesting that the dietary choline intake was sufficient.
- Olthof MR, et al. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans. PLoS Med. (2005)
- Hasengschwandtner F. Phosphatidylcholine treatment to induce lipolysis. J Cosmet Dermatol. (2005)
- Klein SM, et al. In vitro studies investigating the effect of subcutaneous phosphatidylcholine injections in the 3T3-L1 adipocyte model: lipolysis or lipid dissolution. Plast Reconstr Surg. (2009)
- Rittes PG. The lipodissolve technique: clinical experience. Clin Plast Surg. (2009)
- Rotunda AM, et al. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg. (2004)
- Mathur SN, et al. Phosphatidylcholine increases the secretion of triacylglycerol-rich lipoproteins by CaCo-2 cells. Biochem J. (1996)
- Palmer M, Curran J, Bowler P. Clinical experience and safety using phosphatidylcholine injections for the localized reduction of subcutaneous fat: a multicentre, retrospective UK study. J Cosmet Dermatol. (2006)
- Mokosch A, et al. Severe toxic dermatitis after injection lipolysis. Hautarzt. (2012)
- Lichtenstein K, et al. HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms. AIDS Res Ther. (2007)
- Witort EJ, et al. Lipolytic effectiveness of phosphatidylcholine in the treatment of 'buffalo hump' of HIV patients. J Plast Reconstr Aesthet Surg. (2011)
- Salti G, et al. Phosphatidylcholine and sodium deoxycholate in the treatment of localized fat: a double-blind, randomized study. Dermatol Surg. (2008)
- Treacy PJ, Goldberg DJ. Use of phosphatidylcholine for the correction of lower lid bulging due to prominent fat pads. J Cosmet Laser Ther. (2006)
- Tawfik HA, et al. Phosphatidylcholine for the treatment of prominent lower eyelid fat pads: a pilot study. Ophthal Plast Reconstr Surg. (2011)
- Co AC, Abad-Casintahan MF, Espinoza-Thaebtharm A. Submental fat reduction by mesotherapy using phosphatidylcholine alone vs. phosphatidylcholine and organic silicium: a pilot study. J Cosmet Dermatol. (2007)
- Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. (2013)
- Noreldin AA, et al. A Pilot Study on the Use of Injection Lipolysis in Visceral Adipose Tissues. Aesthet Surg J. (2013)
- Noh Y, Heo CY. The effect of phosphatidylcholine and deoxycholate compound injections to the localized adipose tissue: an experimental study with a murine model. Arch Plast Surg. (2012)
- Bechara FG, et al. Induction of fat cell necrosis in human fat tissue after treatment with phosphatidylcholine and deoxycholate. J Eur Acad Dermatol Venereol. (2012)
- Janke J, et al. Compounds used for 'injection lipolysis' destroy adipocytes and other cells found in adipose tissue. Obes Facts. (2009)
- Rittes PG, Rittes JC, Carriel Amary MF. Injection of phosphatidylcholine in fat tissue: experimental study of local action in rabbits. Aesthetic Plast Surg. (2006)
- Salles AG, Valler CS, Ferreira MC. Histologic response to injected phosphatidylcholine in fat tissue: experimental study in a new rabbit model. Aesthetic Plast Surg. (2006)
- Cheatham CL, et al. Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. (2012)